Transforming Breast Cancer Screening with Innovative Technology
Delphinus Medical Technologies and Austin Radiological Association (ARA) have reached an important milestone in women’s health by successfully integrating the SoftVue screening program. SoftVue is the only FDA-approved breast ultrasound tomography system, specifically designed for women with dense breast tissue. This advanced technology aims to improve early detection of breast cancer, addressing a significant health concern for many women.
SoftVue’s Impact on Patient Care
Austin Radiological Association has seen significant enhancements in its patient care approach since launching SoftVue. This innovative screening process provides an additional layer of support for women who have dense breast tissue, which affects nearly 40% of women in the United States. Dense breast tissue can mask the early signs of breast cancer, making it more challenging to detect. With the SoftVue exam, ARA offers a safe and efficient solution that requires no compression and involves no radiation exposure, providing women with a comfortable screening experience.
The Importance of Early Detection
Breast cancer remains a leading concern worldwide, highlighting the need for enhanced screening options. Studies indicate that SoftVue identifies 25% more cancers than traditional mammography in women with dense breasts. By adding this technology to its imaging services, ARA not only improves the rate of early detection but also empowers women to take charge of their health.
Commitment to Patient Experience
Dr. Arthy Saravanan from ARA emphasizes how SoftVue enhances the overall patient experience. By prioritizing advanced imaging technology, ARA ensures women feel comfortable and secure during the screening process. This commitment likely leads to higher compliance rates for annual screenings, ultimately aiming for better health outcomes.
Delphinus Medical Technologies’ Role
Scott White, President & CEO of Delphinus Medical Technologies, articulates the mission of the company, which is to revolutionize the early detection of breast cancer. The partnership with ARA is seen as a significant step toward fulfilling this mission, promoting the adoption of life-saving technology across healthcare settings.
Addressing Gaps in Breast Cancer Screening
ARA’s proactive strategy aligns perfectly with the latest guidelines for breast cancer screening and is a vital response to the needs of women with dense breast tissue. By implementing SoftVue technology, ARA is setting a new benchmark in breast cancer care, ensuring that access to essential screenings becomes even more feasible.
Empowering Women with Information
Debi Brannan, COO of ARA, points out that the launch of their SoftVue program is pivotal for women with dense breast tissue. By broadening access to this innovative technology, ARA is not only enhancing the quality of care but also encouraging women to prioritize regular screenings, which can lead to early detection and potentially save lives.
About Delphinus Medical Technologies and ARA
Delphinus Medical Technologies, headquartered in Novi, Michigan, is recognized as a trailblazer in the field of medical imaging. The SoftVue system is celebrated for its unique 3D breast ultrasound technology that enhances both safety and comfort. With a steadfast commitment to advancing breast cancer screening, Delphinus aims to enhance the lives of women globally.
Meanwhile, Austin Radiological Association, founded in 1954, is a leading diagnostic imaging group known for its expertise in various imaging modalities, including mammography. ARA’s extensive network of board-certified radiologists ensures high-quality patient care, making them a trusted choice for diagnostic imaging in the community.
Frequently Asked Questions
What is SoftVue?
SoftVue is an FDA-approved breast ultrasound tomography system designed to enhance breast cancer screening, particularly for women with dense breast tissue.
Why is it important for women with dense breasts to have specialized screening?
Women with dense breast tissue face challenges in early cancer detection. Specialized screenings like SoftVue help identify cancers that mammograms may miss.
How does SoftVue improve patient comfort during screening?
SoftVue does not require breast compression and uses no radiation, providing a more comfortable experience compared to traditional mammography.
What is the goal of the partnership between Delphinus Medical Technologies and ARA?
This collaboration aims to expand access to advanced breast cancer screening technologies, ultimately improving patient outcomes through early detection.
How does ARA ensure quality imaging?
ARA employs a team of over 115 board-certified radiologists specialized in various fields, ensuring comprehensive and high-quality diagnostic imaging services.
